Home Top Movers Is Check Cap Ltd (CHEK) Stock a buy now?

Is Check Cap Ltd (CHEK) Stock a buy now?

Things have started to change for Check Cap since the NASDAQ compliance re-gain extension. 

The clinical-stage medical diagnostics company shares are trading with strong momentum. The average trading volume of Check-Cap Ltd. (CHEK) is just over 8 million. As we write this on Jan 5., the trading volume is almost 235 million. Is it a good time to jump in and buy the stock?


The 2021 Backdoor Crypto Portfolio (free)

Even if you’re not actively in crypto, you deserve to know what’s actually going on...

Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.

Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free.

Sponsored


What going on?

Check-Cap Ltd. (CHEK) stock is skyrocketing, but what’s the exact reason? On Dec. 30, 2020, the company received a notice of a 180-day extension to regain NASDAQ compliance. This allows the stocks to have enough time to trade above the $1 minimum required share price on the market. 

This NASDAQ compliance extension has driven high volume over the past week. Investors are now seeing things in a positive way as the company tries to fight back.

Back in Nov. 2020, the company announced that it had submitted the Investigational Device Exemption (IDE) application to the FDS for its pivotal study of C-Scan. The IDE is a great achievement towards the initiation of the pivotal study in the U.S. The company is expected to provide updates on its C-Scan study in the near future, following the guidance from the FDA. 

Moreover, the company is preparing well at the backend for the U.S. pivotal study; improving the supply chain, quality controls, and device manufacturing. The company is also managing the expansion of this study at the leading Israeli sites. 

The core objective of Check-Cap is to advance its C-Scan towards the final cynical stages and make it to the market. The C-Scan is being developed as a patient-friendly colorectal cancer (CRC) screening option—detecting pre-cancerous polyps. The company expects a response from the FDA anytime soon.

However, on the other side of the picture, there are concerns regarding Check-Cap’s cash balance. As of Sep. 2020, the company had cash of $21 million with zero debt. Essentially, the cash burn was almost $13 million over the past twelve months. With that, the company had only 19 months of cash runway. The worrying part is that if the company runs out of cash, and that too in the middle of a pandemic. 

Check-cap is still in its early days and is developing as a business. The increase in cash burn shows that the company is focused on future growth and its current focus on its C-Scan pivotal study. 

Conclusion

Wall Street is positive on Check-Cap Ltd. (CHEK) and expects medical diagnostics to grow in the long-term. The game will change once the company receives the guidance update from the FDA on IDE. However, analysts’ rate CHEK stock as a strong buy. The average price target is around $1.7, with an upside of 32% over the next 12 months.

Get The Best Stocks To Trade Every Day!

Join now to get the NewsHeater.com pre-market morning brief 100% free

Must Read

What Has Been Raising The Soleno (SLNO) Stock Up Before Market Open?

In recent premarket trading, Soleno Therapeutics Inc. (SLNO) has soared 3.77% at $1.10 per share. The Soleno stock closed at $1.06 yesterday, down -6.19%. Get...

Stealth BioTherapeutics Corp (MITO) Stock Going Down in PreMarket, Here’s What You Should Know

Stealth BioTherapeutics Corp (MITO) stock prices were up by a colossal 35% as of the market closing on May 6th, 2021, bringing the price...

Why Ocugen, Inc. (OCGN) stock is popping high today?

Shares of Ocugen, Inc. (OCGN) stock were popping high today on May 7, 2021, ahead of today’s earnings report.OCGN stock price saw a surge...

What Is Driving The Powerbridge (PBTS) Stock Higher In Premarket session?

At the last check, Powerbridge Technologies Co. Ltd. (NASDAQ: PBTS) shares were rising 10.71% to trade at $1.55 in premarket trades. The Powerbridge stock...

Beyond Meat, Inc. (BYND) Stock Trending Down After Management’s Uncertainty Over Fiscal Year Guidelines

Beyond Meat, Inc. (BYND) stock prices were down by 2.08% as of the market closing on May 6th, 2021, bringing the price per share...

Regional Health Properties, Inc. (RHE) Stock Skyrockets Following Trading of Exponential Volume of Shares

Regional Health Properties, Inc. (RHE) stock prices soared by 31.4% during early market hours on May 7th 2021, bringing the price per share up...

Orphazyme A/S (ORPH) Stock Plummeting After Failure of ORAIALS-01 Trial Announced

Orphazyme A/S (ORPH) stock prices plummeted by 27.77%  after the market opened on May 7th, 2021, bringing the price per share tumbling down to...

Avalon Holdings Corporation (NYSE:AWX) stock surged in the current trading session; here’s why

At last check, in the current trading session, AWX stock surged by 22.58% to $5.08. AWX stock previously closed the session at $4.14. The...

Related News

Epizyme, Inc. (EPZM) Stock Experiences Volatility Following Disclosure of Q1 2021 Financial Reports

Epizyme, Inc. (EPZM) stock prices were down by 9.44% as of the market closing on May 6th 2021, bringing the price per share down...

Angi Inc. (NASDAQ:ANGI) stock surged in the premarket trading session; here’s why

In the premarket session, Angi Inc. (ANGI) stock surged by 9.69% to $15 at last check. ANGI stock closed previous session at $14.04. The...

CureVac Inc. (NASDAQ: CVAC) stock rises during pre-market. Here’s what’s happening?

CureVac Inc. (NASDAQ: CVAC) stock declined by 7.16% at last close whereas the CVAC stock price gains by 8.44% in the pre-market trading session....

Obalon Therapeutics, Inc. (OBLN) Stock Undergoes Volatility as Pandemic Regulations Relaxed

Obalon Therapeutics, Inc. (OBLN) stock prices were down by 15.13% as of the market closing on May 6th, 2021, bringing the price per share...

Is This Why Nkarta (NKTX) Stock Rises Premarket?

In premarket trading, shares of biopharmaceutical company developing engineered NK cell therapies to treat cancer Nkarta Inc. (NASDAQ: NKTX) rose 14.62% to $29.71 at...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Get The Best Stocks To Trade Every Day!

Join now to get the NewsHeater.com pre-market morning brief 100% free

Get Best Morning Financial Newsletter... 100% Free

Best stocks ideas

Analysts’ Upgrades & Downgrades

Insider Watchlist

Important Earnings

We do not sell or share your information with anyone.

Get The Best Stocks To Trade Every Day!...100% Free

We do not sell or share your information with anyone.

Get The Best Stocks To Trade Every Day!

Join now to get the NewsHeater.com pre-market morning brief 100% free

We do not sell or share your information with anyone.